Areas of Research
Office of the Vice President
Office of Intellectual Property & Commercialization
Office of Sponsored Projects
Compliance & Review Boards
Research Foundation
Forms & Downloads
Funding Opportunities
Policies & Procedures
Proposal Preparation
Resource Links
Routing Proposals
Training & Workshops
Travel FAQs
News Articles
Spotlight Articles
Breeze Newsletter
Events Calendar
Browse Projects
Browse People

Investigating the Annexin A1-Formyl Peptide Receptor Pathway to Develop Innovative Anti-stroke Drugs

Description :  Stroke is the third leading cause of death in the USA, and despite this high mortality, 76% of those having strokes survive, often with moderate or severe disabilities. One of the key therapeutic approaches targets thrombus- the blood clot that occludes the blood vessel. At present, the thrombolytic drug, tissue plasminogen activator (tPA), constitutes the only FDA-approved therapy for acute ischemic stroke. However, the therapeutic window is limited to 3-6 hours from stroke onset, which, combined with haemorrhagic complications, means only 2-3% of US patients receive treatment. Although the exact mechanism(s) responsible for the brain damage occurring after an ischemic insult is/are not fully understood, there is an increasing amount of evidence suggesting that post-ischemia inflammation is a significant contributing factor to the pathogenic process. We, and others, have shed some light on biochemical pathways centered on endogenous inhibitors endowed with counter-regulatory and protective functions. One such biochemical pathway, and potential therapeutic strategy for the treatment of stroke, is the novel target: the Annexin A1-Formyl Peptide Receptor Pathway (or AnxA1-FPR pathway). Whilst our previous data have demonstrated that AnxA1 targets vascular and parenchyma phenomena (via an FPR pathway), little is known about what happens in deep brain structures such as deep cortical layers and the underlying striatum. This project aims to address this lack of knowledge, in order to fully validate this novel target as a potential therapeutic for stroke, and possible other neurovascular diseases. 
Principal Investigator:  Murray, Teresa  --  Biomedical Engineering/CBERS
Funding Agencies:  LSU-HSC
Amount Awarded:  5,350

Start Period:  00/00/0000 End Period:  00/00/0000
Related People
No Affiliated People

November 16th, 2018

Browse Projects

Browse People

Recent Articles

2017 Annual Student Research Symposium...

More News...

Page Tools

Print Page      Email Page

Louisiana Tech University, A Member of the University of Louisiana System
2018 Louisiana Tech University P.O. Box 3178 Ruston, LA 71272